**GENENTECH INC** Form 4 March 31, 2009

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB 3235-0287

**OMB APPROVAL** 

Number: Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

Stock

See Instruction

1. Name and Address of Reporting Person * SANDERS CHARLES A				2. Issuer Name and Ticker or Trading Symbol GENENTECH INC [DNA]					5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First)	iddle)	3. Date of Earliest Transaction					(Check all applicable)				
(Last)	(First)	(IVI)	iddie)			insaction						
1 DNA WA	Y			(Month/Da	•				X Director Officer (given below)		Owner or (specify	
(Street)				4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check				
				Filed(Month/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person				
SO SAN FR	ANCISCO, C	'A 94	4080						Form filed by Person	More than One Ro	eporting	
(City)	(State)	(2	Zip)	Table	I - Non-De	erivative S	Securi	ties Ac	quired, Disposed o	of, or Beneficial	lly Owned	
1.Title of	2. Transaction	Date	2A. Dee	med	3.	4. Securi	ties		5. Amount of	6. Ownership	7. Nature of	
Security	(Month/Day/Year) Execu		Execution	on Date, if TransactionAcquire			Acquired (A) or		Securities Form: Direct I		Indirect	
(Instr. 3)			any		Code	Disposed	of (D	)	Beneficially	(D) or	Beneficial	
			(Month/	Day/Year)	(Instr. 8)	(Instr. 3,	4 and	5)	Owned Following	Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
							(A) or		Reported Transaction(s)			
					Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Common	03/26/2009				D	2,000	D	\$ 95	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: GENENTECH INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Ar Underlying Se (Instr. 3 and 4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 18.6	03/26/2009		D	5,000 (2)	04/23/2003(3)	04/23/2013	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 21.47	03/26/2009		D	40,000 (2)	11/30/1999(3)	11/30/2009	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 26.1	03/26/2009		D	20,000 (2)	05/10/2001(3)	05/10/2011	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 32.84	03/26/2009		D	8,000 (2)	05/15/2000(3)	05/15/2010	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 54.39	03/26/2009		D	39,800 (2)	04/16/2004(3)	04/16/2014	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 58.63	03/26/2009		D	20,000 (2)	04/14/2005(3)	04/14/2015	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 74.06	03/26/2009		D	15,000 (2)	10/15/2008(3)	04/15/2018	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 80.4	03/26/2009		D	15,000 (2)	04/20/2006(3)	04/20/2016	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 82.4	03/26/2009		D	11,000 (2)	10/20/2007(3)	04/20/2017	Common Stock

# **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
	X					

Reporting Owners 2

SANDERS CHARLES A 1 DNA WAY SO SAN FRANCISCO, CA 94080

### **Signatures**

By: ADAM B. LAUTNER For: CHARLES A. SANDERS

03/30/2009

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposed of pursuant to the Agreement and Plan of Merger between the issuer, Roche Holdings Inc. and Roche Investments USA dated March 12, 2009.
- (2) At the effective time of the merger, this option vested in full and was cancelled in exchange for a cash amount equal to the net value of the exercise price and the merger consideration.
- (3) At the effective time of the merger, this option vested in full and was cancelled in exchange for a cash amount equal to the net value of the exercise price and the merger consideration.
- (4) At the effective time of the merger, this option vested in full and was cancelled in exchange for a cash amount equal to the net value of the exercise price and the merger consideration.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3